Overview of Cofsed

Cofsed is a fixed-dose combination (FDC) preparation, typically supplied as an oral solution or syrup, designed to provide comprehensive symptomatic relief for upper respiratory conditions. It is broadly classified as a Combination Cough and Cold Preparation, integrating multiple agents to target the interconnected symptoms of cough, congestion, and allergy.

Quick Facts

Property	Description
Active Ingredients	Chlorpheniramine, Ephedrine, Pholcodine
Form	Oral Solution (Syrup)
Pharmacological Class	Antihistamine, Decongestant, Antitussive
Common Use	Symptomatic relief of cough and cold symptoms
Origin	Synthetic Compounds

Identification and Components

Cofsed's core identity lies in its triple composition of Chlorpheniramine (an antihistamine), Ephedrine (a sympathomimetic amine), and Pholcodine (an opioid derivative antitussive). This combination leverages three distinct pharmacological classes, a strategy clinically recognized for maximizing the scope of symptom control in patients suffering from multi-faceted cold symptoms. The preparation is formulated for oral (systemic) administration and consists of synthetic compounds. This combination is distinguished by the inclusion of Pholcodine, a potent antitussive, and the first-generation antihistamine Chlorpheniramine, which are known for producing central nervous system effects.

Pharmacological Role and General Purpose

Cofsed functions as a multi-action symptomatic agent, supporting the patient's well-being during the acute phase of illness. The general therapeutic purpose is to deliver coordinated and comprehensive symptomatic relief for the main manifestations of upper respiratory irritation, including nasal congestion, allergy-related symptoms, and a persistent non-productive cough. The rationale for combining the agents is rooted in treating these typically co-existing symptoms together. This allows the preparation to efficiently alleviate discomfort across the entire symptom profile in a single FDC.

What side effects are possible with Cofsed?

Possible Side Effects and Safety Information

The safety profile of Cofsed, a combination product containing Chlorpheniramine, Ephedrine, and Pholcodine, is defined by the regulatory classification of adverse reactions across several physiological systems. These classifications are based on official government regulatory documents.

Frequency-Classified Adverse Reactions

The most common adverse reactions documented in regulatory sources typically involve the Central Nervous System (CNS), including drowsiness, sedation, and dizziness, along with dry mouth and constipation.

Less uncommon or rare reactions may affect the Cardiovascular System (e.g., tachycardia, palpitations, hypertension), the Urinary System (e.g., urinary retention), and may include skin rashes or other hypersensitivity reactions.

System-Organ Class Groupings

Adverse effects are formally grouped into System-Organ Classes (SOC) consistent with regulatory reporting standards. Key systems involved include:

Nervous System Disorders (e.g., somnolence, headache)
Cardiac and Vascular Disorders (related to sympathomimetic activity)
Gastrointestinal Disorders (e.g., dry mouth, constipation)

Serious Adverse Reactions and Restrictions

Official labels document the risk of serious adverse reactions, including respiratory depression (due to the opioid component, Pholcodine) and the potential for a severe hypertensive crisis (due to Ephedrine), particularly when used with contraindicated medications. Use is officially restricted in patients with pre-existing conditions such as severe hypertension, severe coronary artery disease, or angle-closure glaucoma.

Population-Specific and Time-Related Safety Notes

Regulatory documents specify that older adults may have heightened sensitivity to CNS effects, such as confusion, and an increased risk of urinary retention. CNS effects may be more pronounced at treatment initiation. Furthermore, the inclusion of Pholcodine introduces a documented regulatory constraint regarding the potential for dependence and abuse with repeated or prolonged exposure.

Overdose and Emergency Response

The official regulatory profile for Cofsed overdose describes manifestations of severe toxicity involving multiple physiological systems. Documented symptoms include significant Central Nervous System (CNS) effects, ranging from agitation, delirium, and convulsions (seizures) to profound drowsiness and potentially coma. The combination of active components results in severe cardiovascular instability, which presents as life-threatening cardiac arrhythmias, tachycardia, and critical blood pressure changes (hyper- or hypotension).

The most severe outcomes documented in the regulatory information include respiratory depression and apnea, which are considered life-threatening and require immediate intervention. Due to the multi-component nature, a complex toxicological syndrome may be present, necessitating specialized care.

Immediate medical attention must be sought for any suspected ingestion beyond the recommended dosage. Regulatory guidance explicitly states that emergency services must be contacted immediately if severe manifestations are observed, such as loss of consciousness or trouble breathing. Management protocols described in official documents rely on symptomatic and supportive treatment, often requiring continuous cardiac monitoring and hospitalization for observation, particularly given the elevated risk in children and older adults. Specific procedures, such as the use of Activated Charcoal or Benzodiazepines for seizures, are documented for managing the toxicological presentation.

Therapeutic Uses of Cofsed

What Cofsed Treats: Main Uses and Benefits

Cofsed is a multi-action preparation generally utilized for the symptomatic management of acute symptoms that interfere with daily functioning associated with common upper respiratory illnesses and seasonal allergies. The preparation is commonly used across therapeutic domains where short-term symptomatic assistance is needed for cold and flu symptoms.

The preparation is applied in addressing conditions characterized by periods of heightened symptoms, relevant in clinical settings that involve acute symptom patterns. The primary indications include symptomatic relief for the common cold, flu-like illness, and allergic rhinitis. The preparation is relevant for easing symptom clusters that may become intense, specifically focusing on three domains: non-productive (dry) cough, nasal congestion, and allergy-related manifestations like sneezing and runny nose. This approach contributes to easing the overall symptom load when multiple symptoms occur together. Cofsed supports the patient during episodes of heightened discomfort by easing distressing symptoms related to heightened physiological activity. “...The multi-action strategy is applicable in scenarios where additional management of discomfort is required, and may assist with maintaining functional stability and helps improve day-to-day comfort.”

Quick Fact: Relevant for Managing Irritative Cough, Congestion, and Allergic Runny Nose

Regulatory References

European Commission document on Cofsed Linctus

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Official regulatory documents define strict limitations on who can and cannot use Cofsed, an FDC containing Chlorpheniramine, Ephedrine, and Pholcodine. Eligibility is defined by age, concurrent medication use, underlying health status, and regional authorization status.

Classification	Regulatory Status / Restriction
Age-Based Non-Eligibility	Not indicated for patients under 18 years of age [Source 1.1]. Not generally recommended for children under 6 years [Source 2.6].
Absolute Contraindications	Contraindicated in patients with severe hypertension, severe coronary artery disease, narrow-angle glaucoma, urinary retention, or those taking MAO inhibitors or within 14 days of cessation [Source 1.1].
Physiological/Reproductive Status	Not recommended during pregnancy or for breastfeeding mothers [Source 1.1].
Conditional Use	Use requires caution in the elderly population and patients with severe renal or hepatic impairment [Source 1.1].

Eligibility is also severely constrained by the Pholcodine component. In territories such as the European Union, the United Kingdom, and Australia, this component has been subject to market withdrawal, rendering the product non-eligible for use [Source 2.5, 3.2]. Additionally, prior use of Cofsed in the 12 months before general anaesthesia involving neuromuscular blocking agents (NMBAs) is a documented risk factor for perianaesthetic anaphylaxis [Source 3.4].

What should I know about interactions with other medicines?

The official interaction profile for Cofsed is defined by the cumulative effects of Chlorpheniramine, Ephedrine, and Pholcodine, leading to documented constraints in CNS function and cardiovascular safety.

Interaction Classifications and Restrictions

Classification Summary	Contextual Constraint
Contraindicated Combinations: MAOIs, Indirect Sympathomimetic Agents, Vasoconstrictor Ergot Alkaloids, Linezolid, Alpha Sympathomimetics.	Timing Rule (MAOIs): Must not be used concurrently or within a 14-day washout period of cessation.
Significant Risk: CNS Depressants, Alcohol, Urinary Alkalinizing Agents, Neuromuscular Blocking Agents.	Population Note: Caution is advised in renal or hepatic impairment due to potential for increased interaction severity.

Official Interaction Statements

The combination is strictly prohibited with all Monoamine Oxidase Inhibitors (MAOIs) and agents like Indirect Sympathomimetics (e.g., Pseudoephedrine) due to documented risk of hypertensive crisis or enhanced sympathetic action.
Pharmacodynamic synergism results in additive CNS Depression when used concurrently with Alcohol or other CNS depressants, including opioid analgesics and sedatives.
Urinary Alkalinizing Agents (e.g., Sodium Bicarbonate) are documented to increase Ephedrine plasma concentrations by decreasing its renal excretion (Pharmacokinetic alteration).
Prior use of the Pholcodine component is an officially noted risk factor for perioperative anaphylaxis when using Neuromuscular Blocking Agents, a risk that may persist for up to 12 months.

Connection to the overall interaction profile

Regulatory documents define the product's interaction structure based on the cumulative pharmacodynamic effects of the three components on the central nervous and cardiovascular systems. These documents officially establish absolute contraindications and mandatory timing rules to mitigate the risks of severe synergistic effects like hypertensive crisis or profound CNS depression. Furthermore, official labeling identifies specific pharmacokinetic and renal transporter interactions that alter the plasma exposure of the drug itself or co-administered medicines.

Mechanism of Action

Cofsed is an FDC that modulates distinct physiological systems by engaging specific molecular targets through simultaneous molecular actions. Its pharmacodynamic action is primarily classified across three mechanistic domains: alpha-adrenergic regulation, central/peripheral H1 blockade, and central mu-opioid agonism.

The mechanism of the decongestant component involves action on the sympathetic nervous system via alpha1-adrenergic receptors and endogenous norepinephrine (NE) release. This causes localized vasoconstriction in the nasal mucosa, initiating a cascading effect that leads to a rapid decrease in tissue volume and vascular volume by limiting fluid extravasation.

Antihistamine action involves the competitive antagonism of H1 receptors and an accompanying anticholinergic action. By blocking the effects of histamine and acetylcholine, the drug interferes with the action of these mediators on capillary permeability and glandular activity, resulting in an alteration of vascular tone and a reduction in respiratory tract secretion volume.

The antitussive mechanism focuses on mu-opioid receptor agonism exerted in the medulla oblongata. This central action elevates the cough threshold by modulating the neural transmission of the reflex arc, resulting in a modulation of the motor output of the central reflex arc.

Dosage and Administration Information

Official Administration Guidelines for Cofsed

Cofsed is a fixed-dose combination provided as an oral liquid solution, and its use follows the labeled dosage and administration rules.

Administration Scope

Category	Guideline
Route of Administration	For oral use only, administered as a solution or syrup.
Standard Adult Dosing	The typical dose is 5 mL to 10 mL per administration.
Frequency & Constraint	The dose may be repeated every 4 to 6 hours as needed, but the total intake must not exceed four to six doses in any 24-hour period.
Duration of Use	Use is limited to a short-term course; the product should generally be stopped if symptoms do not improve within 7 consecutive days.
Preparation & Timing	The liquid must be measured using a calibrated measuring device to ensure dosage accuracy, and may be taken with or without food.
Population Adjustments	Older adults should be considered for a lower initial dose due to potential increased sensitivity. Caution is advised for individuals with hepatic or renal impairment.

Resulting Procedural Structure

The official use protocol requires the accurate measurement of the oral solution volume using the provided calibrated tool. The time interval between doses must be a minimum of four to six hours, and the patient must adhere to a strict maximum daily dose to prevent the potential accumulation of the three active ingredients.

Recent Clinical Evidence

Cofsed: Recent Clinical Evidence

Clinical evidence regarding the efficacy and safety of Cofsed is generally derived from studies focusing on its individual components (such as guaifenesin, bromhexine, and terbutaline), as high-quality randomized controlled trials (RCTs) specifically for fixed-dose combination formulations are often limited.

Evaluation of Efficacy

Research has explored the role of the components in managing symptoms associated with wet cough, such as those related to bronchitis and other airway infections. Guaifenesin, an expectorant, has been studied for its ability to thin and loosen secretions, which may assist in their expulsion. Bromhexine, a mucolytic, is investigated for its potential to reduce mucus viscosity.

Terbutaline, a bronchodilator component, has been evaluated in various trials for its effect on relaxing airway muscles, which may help improve airflow for individuals with conditions like asthma or chronic obstructive pulmonary disease (COPD).

Available trial data on combination formulations like Cofsed often report findings based on changes in symptom scores. Some studies suggest the combination may be associated with an improvement in cough and cold symptoms, although the strength of the evidence is mixed.

Safety Profile in Research

The safety profile is primarily understood through the known effects of the individual active ingredients. Common side effects reported across studies of these ingredients include symptoms such as:

Dizziness
Nervousness or tremors
Stomach discomfort or nausea

Patients with pre-existing conditions, particularly cardiovascular disease, diabetes, or hyperthyroidism, are noted in research protocols as populations requiring careful observation due to the effects of the bronchodilator component. Further large-scale, long-term studies are needed to fully characterize the specific efficacy and safety of the fixed-dose combination over extended periods.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Cofsed (FAQ)

Q: What is the main reason people are prescribed Cofsed?

A: Cofsed is an official fixed-dose combination (FDC) product. According to official documents, it is indicated for the symptomatic relief of conditions related to its three components: a decongestant, an antihistamine, and an antitussive. The drug works by modulating these different physiological systems simultaneously.

Q: Is Cofsed available in different forms (like liquid or tablet)?

A: Official administration guidelines describe Cofsed as being provided as an oral liquid solution or syrup. The product is officially classified and available as an oral liquid solution or syrup.

Q: How long does one dose of Cofsed typically stay active?

A: Regulatory documents indicate that Cofsed is intended for short-term relief. Official dosing instructions recommend that the dose may be repeated every 4 to 6 hours. This time frame provides the recommended interval between doses defined by the official instructions.

Q: Can Cofsed be taken at any time of day?

A: Official safety information notes that Cofsed is associated with common adverse reactions, including drowsiness and sedation. These effects are important considerations as they may reduce alertness and could affect daily activities if the drug is taken at certain times of the day.

Q: If I feel better, is it okay to stop taking Cofsed?

A: Cofsed is officially labeled for use as a short-term course intended to manage temporary symptoms. The product is intended for a short-term course of use to manage temporary symptoms.

Q: Does the effect of Cofsed change if used for many years?

A: The official product label states that Cofsed is intended for short-term use only. Official labeling restricts the product to short-term use, and therefore, information on changes in effect over long-term or chronic use is not within the prescribing information.

Q: Is it normal to still have some symptoms while using Cofsed?

A: Official guidelines specify that treatment should generally be stopped if symptoms do not improve within 7 consecutive days. These guidelines provide the parameter for when to discontinue use based on the absence of sufficient symptom improvement.

Q: Is Cofsed a drug that requires regular follow-up tests?

A: The product is associated with adverse reactions that can affect the Cardiovascular System, such as changes in blood pressure. For individuals with pre-existing conditions, regulatory documents indicate that close observation may be necessary due to potential adverse reactions affecting the Cardiovascular System.

Q: Why are people with certain heart conditions told to be careful with Cofsed?

A: Official labels document the risk of cardiovascular effects, such as palpitations and hypertension (high blood pressure). These reactions are directly related to the sympathomimetic activity of one of the drug's components, which can affect the heart and vascular system.

Q: Can Cofsed cause problems with driving or operating machinery?

A: The official safety information lists drowsiness, sedation, and dizziness as common adverse reactions. Due to these effects on the central nervous system (CNS), the use of Cofsed may impair the ability to perform activities that require complete mental alertness.

Q: Does Cofsed interact with common medicines for pain relief?

A: Regulatory documents note that the combination may cause additive CNS depression when used with other CNS depressants, which includes opioid analgesics (a class of pain relievers). This synergistic effect is a significant safety constraint defined by official sources.

Q: Can I take Cofsed with my usual daily vitamins or supplements?

A: Regulatory documents describe strict prohibitions against co-administration with other Indirect Sympathomimetic Agents or Alpha Sympathomimetics. Patients should be aware that some vitamins and supplements may contain these components.

Q: Can women who are pregnant or breastfeeding use Cofsed?

A: Official drug documents require a discussion of the potential risks to the fetus or infant when considering use during pregnancy or lactation. For this reason, official sources advise caution for pregnant or breastfeeding women.

Q: Are there special considerations for using Cofsed in children?

A: Regulatory guidance for combination products containing these classes of ingredients often advises against their use in children under a specific age (such as 4 or 6 years old). This is due to safety concerns unless the product is specifically labeled and studied for that age group.

Q: Does Cofsed have a specific ingredient that causes dryness?

A: Yes, one of the components has an action called anticholinergic action. This mechanism is responsible for reducing secretions and is associated with the common side effect of dry mouth, as documented in regulatory safety information.

Q: What happens if I take too much Cofsed?

A: Regulatory documents include information on the potential signs and symptoms of overdose or toxicity. These effects are often related to excessive depression of the central nervous system (CNS) or enhanced sympathetic action in the body.

Q: What does 'contraindication' mean in the context of Cofsed?

A: In regulatory context, a contraindication is a condition or circumstance that makes the use of Cofsed highly inadvisable. The risk of harm in these situations is considered high enough that the drug must be absolutely prohibited.

Q: Why does the official document for Cofsed mention a certain risk factor?

A: Regulatory documents officially establish strict rules, such as absolute contraindications and mandatory timing, to mitigate severe risks. These rules are in place to prevent severe synergistic effects, such as a hypertensive crisis (dangerously high blood pressure) or profound CNS depression.

Q: If I miss taking Cofsed, what happens?

A: Official drug information advises that if a dose is missed, it should not be taken if it is close to the time of the next scheduled dose. Furthermore, a double dose should not be taken to make up for the missed one.

Q: Is Cofsed a controlled substance?

A: Regulatory documents include a documented constraint regarding the potential for dependence and abuse with repeated or prolonged exposure. This risk is related to the Pholcodine component and is a key factor considered by regulatory bodies for substance classification.

Q: What is the likelihood of developing a tolerance to Cofsed?

A: The official label includes a regulatory constraint concerning the potential for dependence and abuse due to the presence of Pholcodine. This is a related safety consideration that may involve the body needing a higher amount of the substance over time.

Q: What are the typical signs of an allergic reaction to Cofsed?

A: Less common or rare adverse reactions documented in regulatory safety profiles may include skin rashes or other hypersensitivity reactions.

Q: What is the difference between the active and inactive ingredients in Cofsed?

A: The active ingredients (Chlorpheniramine, Ephedrine, Pholcodine) are the components that produce the pharmacological effect in the body. Inactive ingredients are used to formulate the product, giving it volume, flavor, or color, but do not produce a therapeutic effect.

Q: How is Cofsed removed from the body?

A: The process by which the body removes the drug is called pharmacokinetics. Regulatory documents indicate that the Ephedrine component is primarily removed from the body via renal excretion (through the kidneys), a process that can be altered by other interacting agents.

Q: Are there specific storage rules for Cofsed?

A: Yes, official handling requirements state that Cofsed must be stored at Controlled Room Temperature. This temperature range is officially defined by regulatory agencies as 20 C to 25 C.

Q: Can I get Cofsed without a prescription?

A: The drug is designated by regulatory agencies as a product requiring a prescription or falling under a specific classification that dictates its dispensing status.

How should Cofsed be stored and disposed of?

Storage and Handling Requirements

Cofsed (oral solution) must be stored at Controlled Room Temperature, which is defined by regulatory agencies as 20 C to 25 C (68 F to 77 F). The product must be protected from light and moisture and should be stored in its original container with the cap tightly closed. It is a mandatory requirement to keep Cofsed out of the sight and reach of children to prevent accidental ingestion, particularly given its potent ingredients.

Crucially, the medication must not be frozen.

Official Disposal Instructions

Disposal instructions from official sources recommend utilizing a drug take-back program if available. If a take-back program is unavailable, the unused medicine should be mixed with an undesirable substance (such as dirt or coffee grounds) and sealed in a container before being placed in household trash. All personal identifying information must be removed from the prescription label before discarding the original container.

Cofsed